spacer
home > pmps > winter 2019 > the heart of healthcare
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Heart of Healthcare

Over the last decade, many pharmaceutical companies have moved from mass market drug development to investing in niche speciality medicines. This shift in the pharma industry has been driven by the recognition that the sector’s traditional blockbuster model had become unsustainable.

This is good news for patients with rare diseases. The rise of speciality treatments for chronic, complex, and rare conditions has seen many breakthrough treatments being brought to market and offering new hope to patients.

According to IQVIA (formerly Quintiles and IMS Health), speciality medicines have enjoyed a decade of continued growth, which has put them on course to overtake the value of spending on traditional drugs in many of the world’s biggest pharma markets by 2022.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonathan Chapper is the CEO at CHAPPER healthcare. He joined CHAPPER healthcare in 2013 from a successful career in law, where he worked at leading city law firms, as well as in an investment bank. Jonathan brought with him a wealth of commercial and legal experience, which he now applies to the pharma industry. CHAPPER healthcare is a leading specialist wholesaler and distributor and supplies pharmaceuticals to over 60 countries worldwide.
spacer
Jonathan Chapper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Manufacturing Consultancy up 150% as Life Sciences prepare for a digital future

Zenith Technologies, a world leader in delivering manufacturing software solutions to the life sciences industry, has seen a 150% rise in demand for its consultancy arm services.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement